Study population
blood glucose, ICH, thrombocytopenia, bowel obstruction, constipation, congestive heart failure, coagulopathy, chronic constipation, acute kidney injury
UNSTABLE ANGINA PECTORIS, LIVER FAILURE, THROMBOCYTOPENIA, BOWEL OBSTRUCTION, CARDIAC ARRHYTHMIA, CONGESTIVE HEART FAILURE, COAGULOPATHY, HYPERTHYROID, HYPERTENSION, DRUG ALLERGY
The study design was a single-centre prospective randomized controlled trial with approval by the Khon Kaen University Ethics Committee for Human Research based on the Declaration of Helsinki and the ICH Good Clinical Practice Guidelines (HE621471). The study protocol was registered at the Thai Clinical Trials Registry (TCTR) on 11/04/2023 (ID TCTR20230411007). Patients were scheduled for colonoscopy at the endoscopic unit of Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand, between February 2020 and February 2021. The inclusion criteria were patients 18–75 years of age who were indicated for colonoscopy and had constipation (compatible with the ROME IV diagnostic criteria for chronic constipation or the history of Bristol stool form scale 1–2). The exclusion criteria included suspected bowel obstruction or perforation, contraindication to general anaesthesia, uncontrolled condition such as congestive heart failure, unstable angina pectoris, unstable hypertension, cardiac arrhythmia, liver failure, acute kidney injury, uncontrolled blood glucose, hypo- or hyperthyroid state, inability to stop warfarin for 3 days, inability to stop antiplatelet therapy for 7 days, history of colectomy, pregnancy or breastfeeding, history of drug allergy for PEG-ELS or lubiprostone, coagulopathy (INR > 1.5), and thrombocytopenia (< 50,000/µl).